Evidence map›Paper›PMID 25523923›Full record

ArticleJournal of immunological methods2015

Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.

Benjamin M Kagina, Nazma Mansoor, Eloi P Kpamegan, Adam Penn-Nicholson, Elisa Nemes, Erica Smit, Sebastian Gelderbloem, Andreia P Soares, Brian Abel, Alana Keyser and 6 more

Open access · greenAbstract read
In one paragraph

Article in Journal of immunological methods, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. A 2-Dose AERAS-402 Regimen Boosts CD8Frontiers in immunology · 2021
    Article
  19. Article
  20. Cell-Mediated Immune Responses toFrontiers in immunology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Benjamin M KaginaSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; Vaccines for Africa Initiative, Division of Medical Microbiology & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
Nazma MansoorSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; BD Biosciences, Johannesburg, South Africa.
Eloi P KpameganAeras, Rockville, MD, USA.
Adam Penn-NicholsonSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa.
Elisa NemesSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa.
Erica SmitSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa.
Sebastian GelderbloemAeras, Cape Town, South Africa.
Andreia P SoaresSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
Brian AbelSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; Singapore Immunology Network, Agency for Science, Technology and Research, Singapore.
Alana KeyserSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa.
Mzwandile SidibanaSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa.
Jane E HughesSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa.
Gilla KaplanPublic Health Research Institute, NJMS Rutgers, Newark, NJ, USA; Bill & Melinda Gates Foundation, Seattle, WA, USA.
Gregory D HusseySouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa; Vaccines for Africa Initiative, Division of Medical Microbiology & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
Willem A HanekomSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa. Electronic address: thomas.scriba@uct.ac.za.
South African Tuberculosis Vaccine Initiative · ZAUniversity of Cape Town · ZAAeras · USAgency for Science, Technology and Research · SGBill & Melinda Gates Foundation · US

Funding

Host determinants of protection against tuberculosis in adolescentsR01AI087915 · NIAID · UNIVERSITY OF CAPE TOWN · PI SCRIBA, THOMAS JENS · 2011 to 2015
$3.3M
NIAID NIH HHS R01 AI087915NIAID NIH HHS R01AI087915
6 · The paper itself

Abstract

backgroundQualified or validated assays are essential in clinical trials. Short-term stimulation of whole blood and intracellular cytokine staining assay is commonly used to measure immunogenicity in tuberculosis vaccine clinical trials. Previously, the short-term stimulation process of whole blood with BCG was optimized. We aimed to qualify the intracellular cytokine staining process and assess the effects of long-term cryopreservation. Our hypotheses were that the assay is robust in the measurement of the mycobacteria-specific T cells, and long-term cryopreservation of fixed cells from stimulated whole blood would not compromise reliable measurement of mycobacteria induced CD4 T cell immunity.

methodsWhole blood from healthy adults was collected in sodium heparinized tubes. The blood was left unstimulated or stimulated with mycobacterial antigens or mitogens for 12h. Cells were harvested, fixed and multiple aliquots from each participant cryopreserved. Later, mycobacteria-specific CD4 and CD8 T cells expressing IFN-γ, TNF-α, IL-2 and IL-17 were quantitated by flow cytometry. Assay performance characteristics evaluated included limit of quantification and detection, reproducibility, precision, robustness, specificity and sensitivity. To assess the effects of long-term cryopreservation, fixed cells from the stimulated bloods were analysed one week post-cryopreservation and at 3-month intervals over a 3-year period.

resultsThe limit of quantification for the different cytokines was variable: 0.04% for frequencies of IFN-γ- and IL-2-expressing T cells and less than 0.01% for TNF-α- and IL-17-expressing T cells. When measurement of the mycobacteria-specific T cells was assessed at levels above the detection limit, the whole blood intracellular cytokine assay showed high precision that was operator-independent. The assay was also robust: variation in staining conditions including temperature (4 °C or 20-23 °C) and time (45, 60 or 90 min) did not markedly affect quantification of specific T cells. Finally, prolonged periods of cryopreservation also did not significantly influence quantification of mycobacteria-specific CD4 T cells.

conclusionsThe whole blood intracellular cytokine assay is robust and reliable in quantification of the mycobacteria-specific T cells and is not significantly affected by cryopreservation of fixed cells.

Indexed as

AdultAntigens, BacterialBCG VaccineCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCryopreservationCytokinesFlow CytometryHumansInterferon-gammaInterleukin-17Interleukin-2Limit of DetectionMycobacterium bovisReproducibility of ResultsSensitivity and SpecificityAntigens, BacterialBCG VaccineCytokinesIL2 protein, humanInterferon-gammaInterleukin-17Interleukin-2Tumor Necrosis Factor-alphaFlow cytometryIntracellular cytokine staining assayQualificationWhole blood

Identifiers

PMID25523923
PMCPMC4339399
OpenAlexW2035201477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.